Omeros (NASDAQ:OMER) Hits New 1-Year High – Here’s Why

Posted by Francis Steltz on Aug 25th, 2026

Omeros Corporation (NASDAQ:OMER – Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $19.65 and last traded at $19.2040, with a volume of 334942 shares traded. The stock had previously closed at $19.32.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on OMER shares. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Check Out Our Latest Research Report on Omeros

Omeros Price Performance

The firm has a market cap of $1.40 billion, a price-to-earnings ratio of 15.13 and a beta of 2.54. The firm’s fifty day moving average is $11.93 and its 200-day moving average is $11.81.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts anticipate that Omeros Corporation will post -0.37 EPS for the current year.

Insider Buying and Selling

In related news, Director Thomas J. Cable sold 15,000 shares of Omeros stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the sale, the director owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO David J. Borges sold 5,000 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the sale, the chief accounting officer owned 5,000 shares of the company’s stock, valued at $84,750. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC lifted its position in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 800 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Omeros by 16.5% during the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares in the last quarter. State of Wyoming bought a new stake in Omeros during the 4th quarter worth approximately $25,000. AQR Capital Management LLC raised its stake in shares of Omeros by 7.2% in the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,532 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Omeros by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 1,637 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.